← Browse by Condition
Medical Condition
neuroendocrine tumors
Total Trials
9
Recruiting Now
9
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for neuroendocrine tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — neuroendocrine tumors Clinical Trials
How many clinical trials are currently recruiting for neuroendocrine tumors?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for neuroendocrine tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neuroendocrine tumors?
neuroendocrine tumors research spans Phase 1 (5 trials), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neuroendocrine tumors clinical trial?
Eligibility criteria for neuroendocrine tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 5
Phase 2 3
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06638931 Phase 2
Recruiting
Enrollment
28 pts
Location
Brazil
Sponsor
Instituto do Cancer do Estado ...
NCT04339036 Phase 2
Recruiting
Enrollment
70 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn...
NCT07165132 Phase 1
Recruiting
Enrollment
104 pts
Location
United States, Canad...
Sponsor
RayzeBio, Inc.
NCT05000294 Phase 1, Phase 2
Recruiting
Enrollment
29 pts
Location
United States
Sponsor
University of Florida
NCT05918302 Phase 3
Recruiting
Enrollment
170 pts
Location
Belgium, France, Ita...
Sponsor
Grupo Espanol de Tumores Neuro...
NCT07369505 Phase 1
Recruiting
Enrollment
27 pts
Location
Australia
Sponsor
SAPU NANO (US) LLC
NCT06505824 Phase 1
Recruiting
Enrollment
22 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT06242119
Recruiting
Enrollment
25 pts
Location
Poland
Sponsor
Jagiellonian University
NCT05053854 Phase 1
Recruiting
Enrollment
24 pts
Location
Australia
Sponsor
Peter MacCallum Cancer Centre,...
Related Conditions
soft tissue sarcoma (2) prostate cancer (2) urachal cancer (1) parathyroid carcinoma (1) fibrolamellar carcinoma (1) angiosarcoma (1) secretory carcinoma of breast (1) anal neoplasms (1) metaplastic breast carcinoma (1) translocation renal cell carcinoma (1) carcinosarcoma (1) small intestine neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology